Apogee Therapeutics, Inc. (NASDAQ: APGE)

Sector: Healthcare Industry: Biotechnology CIK: 0001974640
P/B 7.61
P/E -17.60
P/S 0.00
Market Cap 4.46 Bn
ROIC (Qtr) -46.26
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 9.85 Mn
Debt/Equity (Qtr) 0.02

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 107.91M provide 26.46x coverage of short-term debt 4.08M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 626.16M provides 63.55x coverage of total debt 9.85M, indicating robust asset backing and low credit risk.
  • Short-term investments of 419.38M provide solid 14.17x coverage of other current liabilities 29.59M, indicating strong liquidity.
  • Long-term investments of 61.64M provide solid 10.68x coverage of long-term debt 5.77M, indicating strategic financial planning.
  • Tangible assets of 626.16M provide robust 21.16x coverage of other current liabilities 29.59M, indicating strong asset backing.

Cons

  • Operating cash flow of (232.47M) barely covers its investment activities of 155.42M, with a coverage ratio of -1.50, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 155.42M provide weak support for R&D spending of 216.50M, which is 0.72x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Short-term investments of 419.38M significantly exceed cash reserves of 107.91M, which is 3.89x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (232.47M) shows concerning coverage of stock compensation expenses of 41.96M, with a -5.54 ratio indicating potential earnings quality issues.
  • Operating cash flow of (232.47M) provides minimal -993.48x coverage of tax expenses of 234000, suggesting potential tax planning inefficiencies or unsustainable tax positions.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 6.95 12.31
EV to Cash from Ops. -18.72 23.25
EV to Debt 441.58 738.44
EV to EBIT -17.17 -9.16
EV to EBITDA -15.60 6.95
EV to Free Cash Flow [EV/FCF] -18.31 21.90
EV to Market Cap 0.97 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 7.61 22.34
Price to Earnings [P/E] -17.60 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -285.15 -27.13
Cash and Equivalents Growth (1y) % -9.15 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -72.96 -46.93
EBITDA Growth (1y) % -57.53 -1.68
EBIT Growth (1y) % -72.80 -56.45
EBT Growth (1y) % -72.80 -12.70
EPS Growth (1y) % -80.99 -28.31
FCF Growth (1y) % -76.58 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 3.17 3.85
Current Ratio 15.86 7.27
Debt to Equity Ratio 0.02 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22